Is GYRE or HCM more undervalued in 2026?

CirclFi compares Gyre Therapeutics, Inc. (GYRE) and HUTCHMED (China) Limited (HCM) using 13 institutional-grade valuation models. GYRE has a Quality of Company score of 8.0/10 while HCM scores 2.5/10.

Which is a better buy — GYRE or HCM?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do GYRE and HCM valuations compare?

GYRE at $5.91 and HCM at $11.45 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

GYRE vs HCM Valuation Comparison 2026 — Intrinsic Value Analysis

GYRE

Pharmaceutical Preparations

Gyre Therapeutics, Inc.

Quality

8.0

out of 10

Value Trap

SAFE

Price

$5.91

Last close

Models

12/13

Active

HCM

Pharmaceutical Preparations

HUTCHMED (China) Limited

Quality

2.5

out of 10

Value Trap

—

Price

$11.45

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	GYRE Fair Value	GYRE Upside	HCM Fair Value	HCM Upside
Bayesian DCF	Intrinsic	$0.52	-91.2%	$3.53	-69.2%
Earnings Power Value	Intrinsic	$0.74	-87.4%	$2.92	-78.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for GYRE vs HCM — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GYRE vs HCM — Which Stock Is More Undervalued?

GYRE scores higher with a 8.0/10 quality rating vs HCM's 2.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Gyre Therapeutics, Inc. (GYRE) and HUTCHMED (China) Limited (HCM) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GYRE currently trades at $5.91 with a QOC of 8.0/10, while HCM trades at $11.45 with a QOC of 2.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).